Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Onco
Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.
More... |
All times are GMT -7. The time now is 04:22 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021